Next Article in Journal
Physiological and Pathophysiological Aspects of Primary Cilia—A Literature Review with View on Functional and Structural Relationships in Cartilage
Next Article in Special Issue
The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia
Previous Article in Journal
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β1-Integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding
Previous Article in Special Issue
Intestinal Macrophages at the Crossroad between Diet, Inflammation, and Cancer
Open AccessReview

Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System

1
Department of Systems Medicine, University of “Tor Vergata”, 00133 Rome, Italy
2
Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia
3
Division of Clinical Biochemistry and Clinical Molecular Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 4957; https://doi.org/10.3390/ijms21144957
Received: 26 June 2020 / Revised: 10 July 2020 / Accepted: 12 July 2020 / Published: 13 July 2020
Tumors of the digestive system, when combined together, account for more new cases and deaths per year than tumors arising in any other system of the body and their incidence continues to increase. Despite major efforts aimed at discovering and validating novel and effective drugs against these malignancies, the process of developing such drugs remains lengthy and costly, with high attrition rates. Drug repositioning (also known as drug repurposing), that is, the process of finding new uses for approved drugs, has been gaining popularity in oncological drug development as it provides the opportunity to expedite promising anti-cancer agents into clinical trials. Among the drugs considered for repurposing in oncology, compounds belonging to some classes of anthelmintics—a group of agents acting against infections caused by parasitic worms (helminths) that colonize the mammalian intestine—have shown pronounced anti-tumor activities and attracted particular attention due to their ability to target key oncogenic signal transduction pathways. In this review, we summarize and discuss the available experimental and clinical evidence about the use of anthelmintic drugs for the treatment of cancers of the digestive system. View Full-Text
Keywords: drug repurposing; colorectal cancer; hepatocellular carcinoma; chemotherapy; benzimidazole; salicylanilide; niclosamide; rafoxanide; STAT3; Wnt/β-catenin drug repurposing; colorectal cancer; hepatocellular carcinoma; chemotherapy; benzimidazole; salicylanilide; niclosamide; rafoxanide; STAT3; Wnt/β-catenin
Show Figures

Figure 1

MDPI and ACS Style

Laudisi, F.; Marônek, M.; Di Grazia, A.; Monteleone, G.; Stolfi, C. Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System. Int. J. Mol. Sci. 2020, 21, 4957.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop